You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Kinetic image cytometry assays for neuronal activity/toxicity

    SBC: VALA SCIENCES, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): The proposed project is a Phase I STTR collaboration between Vala Sciences Inc, a small business that specializes in the development of cell-based high content/high throughput assays, and the Sanford Burnham Medical Research Institute, a worldwide leader in biomedical research. The project will develop an assay (Kinetic Image Cytometer-Neuron, or KIC-Neuron) to ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Peripheral FAAH as a target for novel analgesics

    SBC: Anteana Therapeutics Inc            Topic: NIDA

    DESCRIPTION (provided by applicant): Pain management remains a significant unmet medical need. Anandamide is an endogenous marijuana-like ('endocannabinoid') molecule that plays important roles in the regulation of pain. Previous work has shown that endocannabinoid receptors located outside the central nervous system (CNS) exert a powerful regulatory control over pain initiation. Moreove ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. A safer urinary catheter design to reduce catheter trauma and infections

    SBC: SAFE MEDICAL DESIGN, LLC            Topic: NIDDK

    DESCRIPTION (provided by applicant): In today's device world, products must address soaring healthcare costs under the increased scrutiny of quality and safety. By addressing patient safety, we believe costs can be reduced and quality improved. Non-infectious urethral catheter related complications are one such patient safety problem the US and worldwide health care industry faces. Urethral c ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. High Yield Human Hepatocyte Isolation

    SBC: ORGAN SOLUTIONS, LLC            Topic: NIDDK

    DESCRIPTION (provided by applicant): End-stage liver disease claims about 30,000 lives in the US. Many patients become too ill to tolerate liver transplantation, and even if transplantation were indicated, there is a severe shortage of viable donor organsand only 28% of the wait-listed patients receive transplants. Development and translational studies with novel alternatives to organ transplanta ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. A Luminal Vascular Coating to Prevent Intimal Hyperplasia Following Creation of a

    SBC: Symic Bio, Inc.            Topic: NIDDK

    DESCRIPTION (provided by applicant): This proposal addresses PHS 2012-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42]). More than 20 million American adults (1 in 10) have some level of chronic kidney disease (CDC), with a growing incidence in the aging population. Nearly 400,000 ESRD patients receive some form of dialysis, with t ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. C/EBP-beta PEPTIDES FOR THE TREATMENT OF LIVER INJURY AND FIBROSIS

    SBC: XFIBRA, LLC            Topic: NIDDK

    DESCRIPTION (provided by applicant): Activation of hepatic stellate cells (HSC) is responsible for the development of liver fibrosis in chronic liver diseases of all causes and remarkably, HSC clearance by apoptosis may allow recovery from liver injury andreversal of liver fibrosis. There is full agreement among liver fibrosis experts that inhibiting o reversing HS activation (the therapeutic targ ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. The Development of TLR Antagonists for Therapy of Hepatic Fibrosis and Cirrhosis

    SBC: DYNAVAX TECHNOLOGIES CORPORATION            Topic: NIDDK

    DESCRIPTION (provided by applicant): Hepatic fibrosis (HF) is a major health problem leading to cirrhosis and death. There is currently no pharmacological treatment for HF, and liver transplantation is unable to meet the needs of all patients afflicted with HF. We have shown that chronic liver injury involves the activation of Toll-like receptor 7 (TLR7) and TLR9. We further demonstrated that the ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Development of OCT Imaging Adapter for Interstitial Tissue Imaging

    SBC: WEST FACE MEDICAL DEVICES, INC.            Topic: NIBIB

    DESCRIPTION (provided by applicant): This Phase I STTR Grant Proposal requests 100,000 support for WestFace Medical Device to construct and test the WestFace Imaging Adaptor in conjunction with Ruikang K. Wang, PhD and his laboratory at the University ofWashington. Utilizing optical coherence tomography (OCT), the patented OCT Adaptor (USPTO Pats. # 7,682,089, # 8,057,107, #8,235,602) provides re ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Urinary Biomarkers of Renal Mitochondrial Dysfunction

    SBC: SCHNELLGEN, INC.            Topic: NIEHS

    DESCRIPTION (provided by applicant): The long-term goal of this project is to identify and validate biomarkers of mitochondrial dysfunction due to environmental stressors. Diverse acute insults from surgery, trauma, ischemia/reperfusion (I/R) and drug andenvironmental chemical toxicity lead to mitochondrial dysfunction and result in cell injury and death in many organs/tissues (e.g. heart, lung, b ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Topical Therapeutic to Promote Healing of Chronic Wounds

    SBC: Phoenicia Biosciences, Inc.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Chronic refractory, or non-healing, wounds or ulcerations of the extremities represent a major medical condition affecting millions of patients. A chronic wound is defined as a wound that does not show signs of significant healing, or progresses, after use of topical/surgical treatment measures for six months. Non-healing wounds affect 6.5 million patients, aff ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government